By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Virax Biolabs Group Limited

Virax Biolabs Group Limited (VRAX)

NASDAQ Currency in USD
$0.58
$0.00
+0.03%
Last Update: 11 Sept 2025, 20:00
$2.52M
Market Cap
0.00
P/E Ratio (TTM)
Forward Dividend Yield
$0.52 - $3.62
52 Week Range

VRAX Stock Price Chart

Explore Virax Biolabs Group Limited interactive price chart. Choose custom timeframes to analyze VRAX price movements and trends.

VRAX Company Profile

Discover essential business fundamentals and corporate details for Virax Biolabs Group Limited (VRAX) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

21 Jul 2022

Employees

17.00

CEO

James Foster

Description

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

VRAX Financial Timeline

Browse a chronological timeline of Virax Biolabs Group Limited corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 1 Oct 2025

Earnings released on 2 Jul 2025

Earnings released on 19 Nov 2024

EPS came in at -$0.89 , while revenue for the quarter reached $4.95K , missing expectations by -99.83%.

Earnings released on 20 Aug 2024

EPS came in at -$1.71 , while revenue for the quarter reached $79.92K , missing expectations by -92.01%.

Stock split effective on 18 Dec 2023

Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 30 Sept 2023

EPS came in at -$1.64 , while revenue for the quarter reached $76.50K , missing expectations by -80.88%.

Earnings released on 27 Sept 2023

EPS came in at -$2.58 , while revenue for the quarter reached $2.80K , missing expectations by -98.60%.

Earnings released on 30 Sept 2022

EPS came in at -$1.24 , while revenue for the quarter reached $5.76K .

Earnings released on 12 Aug 2022

EPS came in at -$1.02 , while revenue for the quarter reached -$92.87K .

Earnings released on 30 Sept 2021

EPS came in at -$0.49 .

Earnings released on 31 Mar 2021

EPS came in at -$0.27 , while revenue for the quarter reached $109.82K .

Earnings released on 30 Sept 2020

EPS came in at -$0.30 , while revenue for the quarter reached $14.00K .

VRAX Stock Performance

Access detailed VRAX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run